

**Table 3.5**  
**Verified Outcomes (Annualized Percentages) by Race/Ethnicity for SRC Super Cohort Participants<sup>1</sup>**

Data as of: February 19, 2022; Events through September 30, 2010 and February 19, 2022

	Race/Ethnicity						
	American Indian/ Alaska Native	Asian or Native Hawaiian/ Other Pacific Islander <sup>2</sup>	Hispanic/ Latina	Non-Hispanic Black/African American	Non-Hispanic White	More than one Race	Other/Not Reported
<b>Outcomes through Extension Study 2005-2010</b>							
<b>Number randomized</b>	379	3558	787	142	111050	1119	599
<b>Mean follow-up (months)</b>	115.0	127.6	145.7	137.6	143.4	146.6	106.7
<b>Cardiovascular<sup>3</sup></b>							
CHD <sup>4</sup>	21 (0.58%)	89 (0.24%)	27 (0.28%)	3 (0.18%)	5224 (0.39%)	42 (0.31%)	28 (0.53%)
CHD death <sup>5</sup>	11 (0.30%)	30 (0.08%)	4 (0.04%)	1 (0.06%)	1812 (0.14%)	13 (0.10%)	20 (0.38%)
Clinical MI	13 (0.36%)	68 (0.18%)	23 (0.24%)	2 (0.12%)	3889 (0.29%)	31 (0.23%)	18 (0.34%)
Angina <sup>6</sup>	19 (0.70%)	54 (0.20%)	28 (0.43%)	2 (0.17%)	3470 (0.39%)	35 (0.38%)	15 (0.37%)
CABG/PTCA	19 (0.52%)	80 (0.21%)	39 (0.41%)	2 (0.12%)	5906 (0.44%)	47 (0.34%)	20 (0.38%)
Carotid artery disease	6 (0.17%)	10 (0.03%)	11 (0.12%)	4 (0.25%)	1065 (0.08%)	8 (0.06%)	7 (0.13%)
Congestive heart failure, WHI <sup>6</sup>	19 (0.70%)	33 (0.12%)	12 (0.18%)	2 (0.17%)	2684 (0.30%)	23 (0.25%)	24 (0.59%)
Stroke	19 (0.52%)	98 (0.26%)	19 (0.20%)	6 (0.37%)	4063 (0.31%)	29 (0.21%)	25 (0.47%)
PAD	5 (0.14%)	9 (0.02%)	3 (0.03%)	3 (0.18%)	949 (0.07%)	13 (0.10%)	2 (0.04%)
Coronary disease <sup>7</sup>	52 (1.43%)	177 (0.47%)	71 (0.74%)	7 (0.43%)	11305 (0.85%)	103 (0.75%)	56 (1.05%)
<b>Total cardiovascular disease</b>	<b>68 (1.87%)</b>	<b>288 (0.76%)</b>	<b>99 (1.04%)</b>	<b>20 (1.23%)</b>	<b>16063 (1.21%)</b>	<b>154 (1.13%)</b>	<b>85 (1.60%)</b>
<b>Fractures<sup>3</sup></b>							
Hip fracture	4 (0.11%)	28 (0.07%)	15 (0.16%)	0 (0.00%)	2868 (0.22%)	26 (0.19%)	14 (0.26%)

<sup>1</sup> The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.

<sup>2</sup> Native Hawaiian/Other Pacific Islander SRC Super Cohort participants (n=79) are combined with Asian SRC Super Cohort participants for reporting purposes due to small numbers.

<sup>3</sup> Cardiovascular diseases and hip fracture are not adjudicated for SRC Super Cohort participants during the WHI Extension Study 2010-2025. Reported statistics represent experience during the original program and the Extension Study 2005-2010.

<sup>4</sup> "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Study 2005-2010.

<sup>5</sup> "CHD death" includes definite and possible CHD death.

<sup>6</sup> Angina and CHF are not verified outcomes in the WHI Extension Study 2005-2010. Reported statistics represent experience during the original program.

<sup>7</sup> "Coronary disease" includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, and CABG/PTCA; Q-wave MI, angina and congestive heart failure were not collected in the WHI Extension Study 2005-2010.

**Table 3.5 (continued)**  
**Verified Outcomes (Annualized Percentages) by Race/Ethnicity for SRC Super Cohort Participants<sup>1</sup>**

Data as of: February 19, 2022 Events through September 30, 2010 and February 19, 2022

	Race/Ethnicity						
	American Indian/Alaska Native	Asian or Native Hawaiian/Other Pacific Islander <sup>2</sup>	Hispanic/Latina	Non-Hispanic Black/African American	Non-Hispanic White	More than one Race	Other/Not Reported
<b>Outcomes through Extension Study 2010-2025</b>							
<b>Number randomized</b>	379	3558	787	142	111050	1119	599
<b>Mean follow-up (months)</b>	154.0	178.1	213.1	192.3	210.0	213.9	138.8
<b>Cancer</b>							
Breast Cancer	20 (0.41%)	248 (0.47%)	69 (0.49%)	10 (0.44%)	10619 (0.55%)	86 (0.43%)	35 (0.51%)
Invasive breast cancer	17 (0.35%)	199 (0.38%)	55 (0.39%)	8 (0.35%)	8963 (0.46%)	75 (0.38%)	28 (0.40%)
In situ breast cancer	4 (0.08%)	52 (0.10%)	15 (0.11%)	2 (0.09%)	1841 (0.09%)	13 (0.07%)	8 (0.12%)
Ovarian cancer	3 (0.06%)	15 (0.03%)	3 (0.02%)	1 (0.04%)	1043 (0.05%)	6 (0.03%)	9 (0.13%)
Endometrial cancer <sup>3</sup>	1 (0.04%)	24 (0.07%)	12 (0.14%)	2 (0.19%)	1523 (0.13%)	10 (0.10%)	3 (0.07%)
Colorectal cancer	8 (0.16%)	48 (0.09%)	18 (0.13%)	3 (0.13%)	2499 (0.13%)	15 (0.08%)	9 (0.13%)
Other cancer <sup>4</sup>	31 (0.64%)	240 (0.45%)	65 (0.47%)	15 (0.66%)	14246 (0.73%)	104 (0.52%)	63 (0.91%)
<b>Total cancer</b>	59 (1.21%)	529 (1.00%)	145 (1.04%)	26 (1.14%)	27123 (1.40%)	207 (1.04%)	111 (1.60%)
<b>Deaths</b>							
Cardiovascular deaths	32 (0.66%)	200 (0.38%)	54 (0.39%)	11 (0.48%)	11361 (0.58%)	87 (0.44%)	60 (0.87%)
Cancer deaths	26 (0.53%)	189 (0.36%)	29 (0.21%)	6 (0.26%)	10062 (0.52%)	62 (0.31%)	57 (0.82%)
Other known cause	53 (1.09%)	200 (0.38%)	93 (0.67%)	7 (0.31%)	14172 (0.73%)	125 (0.63%)	53 (0.77%)
Unknown cause	2 (0.04%)	29 (0.05%)	10 (0.07%)	1 (0.04%)	1806 (0.09%)	23 (0.12%)	1 (0.01%)
<b>Total death<sup>5</sup></b>	195 (2.76%)	1298 (1.70%)	331 (1.94%)	54 (1.79%)	54360 (2.37%)	469 (1.95%)	321 (2.97%)

<sup>1</sup> The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.

<sup>2</sup> Native Hawaiian/Other Pacific Islander SRC Super Cohort participants (n=79) are combined with Asian SRC Super Cohort participants for reporting purposes due to small numbers.

<sup>3</sup> Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

<sup>4</sup> Only one report of "other cancer" is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

<sup>5</sup> Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.